AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18607381 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 nmol kg(‐1) PP
Number of subjects: 26
Study 18607381 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 nmol kg(‐1) PYY(3‐36)
Number of subjects: 26
Study 18607381 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 nmol kg(‐1) PP+30 nmol kg(‐1) PYY(3‐36)
Number of subjects: 26
Study 18607381 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 26
Study 18607381 — intervention group
Group type: EXPERIMENTAL
Intervention: PP+PYY
Number of subjects: 26
Study 18607381 — intervention group
Group type: EXPERIMENTAL
Intervention: PP
Number of subjects: 26
Study 18607381 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY
Number of subjects: 26
Study 15647641 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 14
Study 15647641 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 14
Study 15647641 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin vs Octreotide
Number of subjects: 14
Study 12107722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride (5 mg orally three times a day)
Number of subjects: 103
Study 12107722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 103
Study 12107722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride (8 weeks treatment)
Number of subjects: 103
Study 12107722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 10442492 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse (RL) group
Number of subjects: 42
Study 10442492 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission (RM) group
Number of subjects: 42
Study 10442492 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study 7598058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (15,000 and 30,000 micrograms retinol equivalents or 50,000 and 100,000 IU)
Number of subjects: 11918
Study 7598058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11918
Study 2193172 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bacillus Calmette-Guerin (200 mg, 3 times each week)
Number of subjects: 88
Study 2193172 — intervention group
Group type: COMPARATOR
Intervention: Intravesical plus percutaneous bacillus Calmette-Guerin (50 mg weekly for 6 weeks, then at 8, 10, and 12 weeks, then at 6 months and every 6 months thereafter)
Number of subjects: 88
Study 365324 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 200
Study 365324 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 200
Study 30479028 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent polymer drug-eluting stents (PP-DES)
Number of subjects: 50
Study 30479028 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable polymer drug-eluting stents (BP-DES)
Number of subjects: 50
Study 30479028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PP-DES and BP-DES
Number of subjects: 50
Study 27622507 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (OCV)
Number of subjects: 71900
Study 24952227 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) therapy
Number of subjects: 20
Study 24952227 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET analysis 3-6 months after RFA
Number of subjects: 20
Study 22300972 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt tipped chest tube
Number of subjects: 100
Study 22300972 — intervention group
Group type: COMPARATOR
Intervention: Sharp tipped chest tube
Number of subjects: 100
Study 19731119 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone + one Cal+D tablet (500 mg calcium and 200 IU vitamin D) daily
Number of subjects: 140
Study 19731119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen + 2.5 mg medroxyprogesterone (CEE/MPA) + one Cal+D tablet daily
Number of subjects: 140
Study 19731119 — intervention group
Group type: COMPARATOR
Intervention: one Cal+D tablet daily
Number of subjects: 140
Study 18503924 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided glucose management system (CG)
Number of subjects: 40
Study 18503924 — intervention group
Group type: COMPARATOR
Intervention: Standard paper-based insulin protocol
Number of subjects: 40
Study 15922980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 5 mg daily for 1 year
Number of subjects: 40
Study 15922980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg daily for 1 year
Number of subjects: 40
Study 15168910 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA users
Number of subjects: 50
Study 15168910 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA users (greater use)
Number of subjects: 50
Study 15168910 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy MDMA users (>= 50 times)
Number of subjects: 50
Study 15168910 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 50
Study 11045137 — intervention group
Group type: COMPARATOR
Intervention: β-blockers
Number of subjects: 0
Study 11045137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8958387 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) prophylactic treatment for 2 weeks
Number of subjects: 37
Study 8958387 — intervention group
Group type: EXPERIMENTAL
Intervention: PF4-heparin ELISA test
Number of subjects: 37
Study 8958387 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral venography
Number of subjects: 37
Study 8958387 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily platelet count
Number of subjects: 37
Study 1300565 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (Wellferon)
Number of subjects: 44
Study 1300565 — intervention group
Group type: COMPARATOR
Intervention: Prednisone pretreatment
Number of subjects: 44
Study 3862040 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine gluconate mouth rinse, twice daily
Number of subjects: 16
Study 3862040 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 16
Study 30463820 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomization inhalation of terbutaline followed by nebulized inhalation of budesonide
Number of subjects: 240
Study 30463820 — intervention group
Group type: COMPARATOR
Intervention: Atomized inhalation of mixed liquid of terbutaline and budesonide
Number of subjects: 240
Study 27312903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol fixed combination (DTFC)
Number of subjects: 0
Study 24867917 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (n = 20)
Number of subjects: 39
Study 24867917 — intervention group
Group type: COMPARATOR
Intervention: Attention control (education) intervention (n = 19)
Number of subjects: 39
Study 22722632 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi DBS
Number of subjects: 159
Study 22722632 — intervention group
Group type: EXPERIMENTAL
Intervention: STN DBS
Number of subjects: 159
Study 19773416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment
Number of subjects: 395
Study 17494985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette with diagnostic/psychiatric labelling
Number of subjects: 120
Study 17494985 — intervention group
Group type: COMPARATOR
Intervention: Vignette without diagnostic/psychiatric labelling
Number of subjects: 120
Study 17494985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette with symptoms of ADHD (gender-neutral peer)
Number of subjects: 120
Study 15967511 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation plus sertraline
Number of subjects: 24
Study 15967511 — intervention group
Group type: COMPARATOR
Intervention: Sertraline monotherapy
Number of subjects: 24
Study 11812715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 105
Study 11812715 — intervention group
Group type: COMPARATOR
Intervention: 0.125% levobupivacaine
Number of subjects: 105
Study 11812715 — intervention group
Group type: COMPARATOR
Intervention: 0.0625% levobupivacaine
Number of subjects: 105
Study 10568861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (3 mg)
Number of subjects: 44
Study 10568861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 44
Study 10568861 — intervention group
Group type: COMPARATOR
Intervention: Saline (3 ml)
Number of subjects: 44
Study 8908288 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (immunotherapy)
Number of subjects: 109
Study 8908288 — intervention group
Group type: COMPARATOR
Intervention: Control (no OK-432)
Number of subjects: 109
Study 1299793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 56
Study 1299793 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 56
Study 6381015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 43
Study 6381015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30718625 — intervention group
Group type: EXPERIMENTAL
Intervention: 16Δ base‐out prism condition
Number of subjects: 21
Study 30718625 — intervention group
Group type: EXPERIMENTAL
Intervention: -2.50D spherical lenses condition
Number of subjects: 21
Study 30718625 — intervention group
Group type: COMPARATOR
Intervention: Control normal viewing condition
Number of subjects: 21
Study 30260736 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant laser irradiation
Number of subjects: 40
Study 30260736 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval laser irradiation
Number of subjects: 40
Study 30260736 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide disinfection
Number of subjects: 40
Study 30260736 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 27442314 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 group (4 softgels containing 1680 mg eicosapentaenoic acid/560 mg docosahexaenoic acid daily for 12 weeks)
Number of subjects: 105
Study 27442314 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 group
Number of subjects: 105
Study 27442314 — intervention group
Group type: COMPARATOR
Intervention: Control group (3136 mg of linoleic acid daily for 12 weeks)
Number of subjects: 105
Study 23548420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial Multiple Precision Administration of Mononuclear Bone Marrow Cells (MBMC)
Number of subjects: 0
Study 23548420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21926634 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily efavirenz doses of 200, 250, 300, 350 mg based on weight bands
Number of subjects: 41
Study 21926634 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily efavirenz doses
Number of subjects: 41
Study 19346974 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 39
Study 19346974 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 39
Study 16924528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedrest for 14 days
Number of subjects: 26
Study 16924528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedrest for 42 days
Number of subjects: 26
Study 16924528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedrest for 90 days
Number of subjects: 26
Study 16924528 — intervention group
Group type: COMPARATOR
Intervention: Bedrest for 14 days and 42 days
Number of subjects: 26
Study 16924528 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer bedrest durations
Number of subjects: 26
Study 14729722 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-receptor antagonist (16 mg naloxone)
Number of subjects: 34
Study 14729722 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-receptor agonist (60 mg codeine)
Number of subjects: 34
Study 14729722 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 34
Study 11401635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinguecula patients
Number of subjects: 57
Study 11401635 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 9107219 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 105
Study 9107219 — intervention group
Group type: COMPARATOR
Intervention: Skin-prick tests
Number of subjects: 105
Study 9107219 — intervention group
Group type: COMPARATOR
Intervention: Western blot tests
Number of subjects: 105
Study 9107219 — intervention group
Group type: COMPARATOR
Intervention: RAST
Number of subjects: 105
Study 7686065 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave treatment
Number of subjects: 40
Study 7686065 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 40
Study 2826749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice consisting of sodium bicarbonate and 3% hydrogen peroxide or 3% hydrogen peroxide alone with 5 M NaCl irrigating solution
Number of subjects: 10
Study 2826749 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice consisting of sodium bicarbonate and 3% hydrogen peroxide or 3% hydrogen peroxide alone with distilled water as irrigant
Number of subjects: 10
Study 29313172 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased knowledge of recovery
Number of subjects: 224
Study 29313172 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported PCCP behaviors
Number of subjects: 224
Study 29313172 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective fidelity measures
Number of subjects: 224
Study 26906278 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NFT) with a motor imagery-based BCI (MI-BCI)
Number of subjects: 63
Study 26906278 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NFT)
Number of subjects: 63
Study 25032220 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior foot placement
Number of subjects: 45
Study 25032220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands on thigh position
Number of subjects: 45
Study 24171260 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g P. tuberosa in two divided doses
Number of subjects: 15
Study 24171260 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 15
Study 20826076 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile drug court (JDC) intervention
Number of subjects: 118
Study 18096841 — intervention group
Group type: EXPERIMENTAL
Intervention: Small vessel VaD
Number of subjects: 706
Study 18096841 — intervention group
Group type: EXPERIMENTAL
Intervention: Large vessel VaD
Number of subjects: 706
Study 18096841 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall neurological signs
Number of subjects: 706
Study 19369186 — intervention group
Group type: EXPERIMENTAL
Intervention: Six acupuncture points (ST35, EX‐LE4, ST36, SP9, SP10, ST34)
Number of subjects: 70
Study 19369186 — intervention group
Group type: EXPERIMENTAL
Intervention: Two acupuncture points (ST35, EX‐LE4)
Number of subjects: 70
Study 19369186 — intervention group
Group type: COMPARATOR
Intervention: Both groups allowed to take 200 mg celecoxib per day
Number of subjects: 70
Study 19369186 — intervention group
Group type: COMPARATOR
Intervention: Global assessment of change after 10 treatments
Number of subjects: 70
Study 19369186 — intervention group
Group type: COMPARATOR
Intervention: Body weight change
Number of subjects: 70
Study 15889022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegged components
Number of subjects: 43
Study 15889022 — intervention group
Group type: COMPARATOR
Intervention: Keeled components
Number of subjects: 43
Study 12468605 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein diester formulation (0.67 micro mol lutein/kg body)
Number of subjects: 18
Study 12468605 — intervention group
Group type: COMPARATOR
Intervention: Unesterified lutein formulation (0.5 micro mol lutein/kg body)
Number of subjects: 18
Study 12468605 — intervention group
Group type: COMPARATOR
Intervention: Oil-solubilized unesterified lutein preparation (0.5 micro mol/kg body)
Number of subjects: 18
Study 9469323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure antiandrogen plus placebo (A+P group)
Number of subjects: 244
Study 9469323 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonist plus placebo (LHRH+P group)
Number of subjects: 244
Study 9469323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure antiandrogen plus LHRH agonist (A+LHRH group)
Number of subjects: 244
Study 9469323 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo (P+P group)
Number of subjects: 244
Study 9469323 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival comparison among the four arms
Number of subjects: 244
Study 9469323 — intervention group
Group type: EXPERIMENTAL
Intervention: Anandron-containing regimens
Number of subjects: 244
Study 9469323 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH-containing regimens
Number of subjects: 244
Study 9469323 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 244
Study 7848897 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG patches delivering low (15-30 mg/24 hr)
Number of subjects: 562
Study 7848897 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG patches delivering moderate (45-60 mg/24 hr)
Number of subjects: 562
Study 7848897 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG patches delivering large (75 and 105 mg/24 hr)
Number of subjects: 562
Study 7848897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study 2970362 — intervention group
Group type: EXPERIMENTAL
Intervention: Water restriction (1.0 litre total water intake/24 h)
Number of subjects: 9
Study 2970362 — intervention group
Group type: EXPERIMENTAL
Intervention: Water loading (6.8 litres total water intake/24 h)
Number of subjects: 9
Study 2970362 — intervention group
Group type: COMPARATOR
Intervention: Control (2.7 litres water/24 h)
Number of subjects: 9
Study 11799261 — intervention group
Group type: EXPERIMENTAL
Intervention: cerivastatin (0.15 mg/day)
Number of subjects: 60
Study 11799261 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 31727881 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variance influencing cortical thickness in the right dorsal lateral prefrontal cortex (DLFPC) sulci and gyri, ventral posterior cingulate cortex (PCC), pre-somatic motor cortex (PreSMA), medial precuneus, left occipital-temporal junction (OTJ), parietal-temporal junction (PTJ), ventral somatosensory cortex (vSMA), and medial and lateral precuneus.
Number of subjects: 258
Study 31727881 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-half replication of DLPFC clusters.
Number of subjects: 258
Study 31727881 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analytic term search.
Number of subjects: 258
Study 31727881 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene and transcript mapping/enrichment analyses.
Number of subjects: 258
Study 29929783 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN3470-3471-3479
Number of subjects: 24
Study 29929783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26994756 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV+ (Patient-Activated Ventilation Plus)
Number of subjects: 108
Study 26994756 — intervention group
Group type: COMPARATOR
Intervention: CMV (Controlled Mechanical Ventilation)
Number of subjects: 108
Study 25268370 — intervention group
Group type: EXPERIMENTAL
Intervention: BEV-PAC (bevacizumab 10 mg kg(‐1) days 1 and 15 plus paclitaxel 90 mg m(‐2) days 1, 8 and 15 q4w)
Number of subjects: 0
Study 25268370 — intervention group
Group type: COMPARATOR
Intervention: BEV-CAP (bevacizumab 15 mg kg(‐1) day 1 plus capecitabine 1000 mg m(‐2) bid days 1‐14 q3w)
Number of subjects: 0
Study 25268370 — intervention group
Group type: EXPERIMENTAL
Intervention: BEV-PAC
Number of subjects: 0
Study 25268370 — intervention group
Group type: COMPARATOR
Intervention: BEV-CAP
Number of subjects: 0
Study 22518377 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm-long, 4 mm-wide implants
Number of subjects: 40
Study 22518377 — intervention group
Group type: COMPARATOR
Intervention: at least 10 mm-long implants in augmented bone
Number of subjects: 40
Study 20400406 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-IFN alfa-2a / ribavirin
Number of subjects: 289
Study 17509302 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/m2 docetaxel (arm A)
Number of subjects: 40
Study 17509302 — intervention group
Group type: COMPARATOR
Intervention: 25 mg/m2 vinorelbine (arm B)
Number of subjects: 40
Study 17509302 — intervention group
Group type: EXPERIMENTAL
Intervention: Second line vinorelbine after progression to docetaxel
Number of subjects: 40
Study 17509302 — intervention group
Group type: COMPARATOR
Intervention: Second line docetaxel after progression to vinorelbine
Number of subjects: 40
Study 15949359 — intervention group
Group type: COMPARATOR
Intervention: Routine hyperoxic CPB (FiO2 of 1.0)
Number of subjects: 20
Study 15949359 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CPB with graded reoxygenation (FiO2 of 0.21 increased to 30%-60% over 5-10 minutes)
Number of subjects: 20
Study 15949359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 12375715 — intervention group
Group type: EXPERIMENTAL
Intervention: Suplatast tosilate (100 mg t.i.d. for 28 days)
Number of subjects: 28
Study 12375715 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 28
Study 10980831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with agents that lower triglycerides and raise HDL
Number of subjects: 0
Study 10980831 — intervention group
Group type: COMPARATOR
Intervention: High triglyceride levels
Number of subjects: 0
Study 10980831 — intervention group
Group type: COMPARATOR
Intervention: Fasting triglyceride levels
Number of subjects: 0
Study 8850385 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily diltiazem CD
Number of subjects: 95
Study 8850385 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily diltiazem SR
Number of subjects: 95
Study 2185042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with clomiphene citrate (CC)
Number of subjects: 40
Study 2185042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with spontaneous cycles
Number of subjects: 40